Affineon
17 employees on LinkedIn · 8 known investors
Affineon Health builds automation tools for healthcare providers and care teams, reducing administrative and tedious tasks so clinicians can focus on patient care. The company operates in the digital health / healthtech space in the US, aiming to keep care teams continuously connected with patients.
Also known as Affineon Health · Affineon Health, Inc.
Founders & leadership
Investors · 8
Also in the syndicate · 2
Company profile
researched Aug 2026Affineon Health, Inc. develops an AI-powered "inbox" for physicians and care teams that operates natively inside electronic health record systems. Its two core products are Labs Core, which automatically triages normal, clinically insignificant abnormal, and CC'd lab results — routing, grouping, summarizing and trending results, drafting patient notes, and closing items out of the provider inbox — and Rx Renewals, which speeds staff processing of prescription renewal requests and gives prescribers the detail needed plus an indication of whether a request meets their protocol. Protocols and patient messaging are configurable at the practice level so providers retain control.
A third offering, Affineon Embed, is a white-label program allowing EHR vendors, AI scribe and ambient documentation platforms, and other healthcare workflow companies to integrate Affineon's AI inbox into their own products under their own brand. The company states its platform requires no new app, login or workflow change, has processed more than 2,000 different types of labs, and is SOC 2 and HIPAA compliant. Reported outcomes include inbox volume reductions in the 30-80% range and time savings of roughly three to five hours per week per provider.
Founding story
Founded in 2023 with AI Fund, the venture studio launched by Andrew Ng in 2018, as an early investor. David Norris is identified as Co-Founder and CEO in the seed funding announcement.
Business model
B2B SaaS sold to physician practices and health systems on a per-provider, per-month subscription with volume-tiered pricing, plus a white-label/OEM channel (Affineon Embed) through which healthcare software vendors bundle the AI inbox into their own products.
Published subscription pricing runs from $100 per provider per month for a single module (Labs Core or Rx Renewals) at 1-7 providers down to $75 at 100-249 providers, and from $175 to $145 per provider per month for the Labs and Rx bundle across the same tiers; organizations with 250 or more providers are quoted on enterprise terms. Embed partners are positioned as reselling the AI inbox to their own customers for less than $3 per day per provider.
Traction
Reported partnerships with health systems, physician practices and EHRs including athenahealth; a 4.8 rating on the athenahealth Marketplace; more than 2,000 distinct lab types processed; and customer-reported reductions of roughly 40-50% in lab-related administrative workload and inbox volume. Total capital raised stood at $6 million as of the February 2025 seed announcement.
Latest developments
Following the February 2025 seed round, the company said it would accelerate product development across lab results, prescription renewals and patient communication, and expand its market presence. It has launched the Affineon Embed white-label program for EHR systems, AI scribes and other healthcare technology companies, and is recruiting for development and marketing roles in San Francisco and remotely.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positions itself as an AI inbox specialist addressing administrative burden and physician burnout, differentiated from AI scribe and ambient documentation vendors and pitched to them as a complementary embedded capability. Press coverage describes the company as a provider of AI-powered workflow automation for physicians.
Operates inside the existing EHR inbox with no separate app, login or workflow change; practice-level configurability of protocols and patient messaging so clinicians retain control; automation of both normal and defined clinically insignificant abnormal results rather than summarization alone; and availability as an embeddable white-label component for other health IT vendors.
Technology
Agentic AI that operates within the EHR inbox rather than as a separate application. Capabilities include smart filtering and routing of CC'd labs, grouping of incomplete lab sets, automated processing of normal and configurable clinically insignificant abnormal results with patient notification, chart-wide summarization and trending of results, automated ASCVD and CKD risk calculation based on ACC/AHA and ISN evidence-based guidance, AI-drafted patient notes for provider review, and retroactive clean-up of historical labs. The company states SOC 2 and HIPAA compliance.
Go-to-market
Direct sales to practices via demo requests and a satisfaction-guaranteed trial, distribution through the athenahealth Marketplace where the product carries a 4.8 rating, and channel partnerships with EHR vendors, AI scribe platforms and workflow software companies through the Affineon Embed white-label program. Customer case studies and provider testimonials are used as sales collateral.
Ambulatory physician practices, health systems and their care teams — primary care and specialty providers, nurses and administrative staff burdened by EHR inbox volume — plus healthcare technology vendors including EHR systems, AI scribe/ambient platforms and care-coordination workflow companies as Embed partners. The contact form lists AllScripts, Athena, Cerner, eClinicalWorks, Epic, Greenway, Meditech and NextGen among customer EHRs.
Geography
United States. Press coverage identifies the company as Denver, Colorado-based, while job listings are posted for San Francisco and remote roles.
History
Founded in 2023. The company raised early backing from AI Fund and closed a $5 million oversubscribed seed round announced on 3 February 2025, led by GPG Ventures, bringing total capital raised to $6 million and funding accelerated product development and market expansion.
Risks & controversies
Many performance figures — inbox volume reduction, hours saved and workload reduction percentages — are self-reported by the company or drawn from customer testimonials rather than independent evaluation, and the stated inbox reduction range varies across company materials (50-60%, 30-80%, and up to 80%). Leadership attribution differs between sources: the funding announcement names David Norris as Co-Founder and CEO while the company team page lists Evan Grossman as Chief Executive Officer. The business depends on integrations with third-party EHR platforms and, for the Embed channel, on partner vendors.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsAffineon Health announced a $5 million oversubscribed seed round led by GPG Ventures with participation from existing investor AI Fund and new investors Deepwater, Benhamou Global Ventures, Headwater Ventures and Signal Peak Ventures. Proceeds are earmarked for product development and market expansion, bringing total capital raised to $6 million.
$5M source ↗
Company reported market traction through partnerships with health systems, physician practices and EHR vendors such as athenahealth; Affineon is listed on the athenahealth Marketplace.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Affineonaffineon.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Affineon do?
- Affineon builds an AI inbox that works inside EHR systems to automate lab result triage and prescription renewals for providers.
- Who founded Affineon?
- Affineon was founded by Ryan Van Wert.
- Who are Affineon's investors?
- Affineon's investors include AI Fund, Benhamou Global Ventures, City Light, Headwater Ventures, Loup Ventures, Signal Peak Ventures.